Clinical trial NCT05013216: Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Official title: Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: High Risk Cancer
Pancreatic Cancer
Keywords: KRAS Peptide Vaccine
Neoantigen Vaccines
Cancer Vaccines
Immunotherapy
Pancreatic Ductal Adenocarcinoma (PDAC)
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor class: OTHER
Collaborators: name: Stand Up To Cancer
name: National Cancer Institute (NCI)
First posted: 2021-08-19
Enrollment: 37
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: This Phase 1 study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine with poly-ICLC adjuvant for patients who have been identified to be at risk of developing pancreatic cancer.

Detailed description: This study will evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant. The primary endpoints of this study are to determine the safety of administering the KRAS peptide vaccine with poly-ICLC adjuvant and to assess the maximal percent change of IFN-γ-producing mutant-KRAS-specific T cells per patient at any time after vaccination. Twenty five patients will be enrolled to achieve 20 evaluable patients for Cohort A. Twelve patients will be enrolled to achieve 10 evaluable patients for Cohort B.

For all patients, the study will consist of a screening phase, treatment phase, and a follow-up visit. All subjects will have the option remaining on study with annual follow-up visits that begin approximately one year after the last vaccine dose and continue annually thereafter until study closure.

Eligibility criteria: Inclusion Criteria:

Cohort A: Must fall into one of the three categories defined as high risk of developing pancreatic cancer and are undergoing pancreatic surveillance AND 2) have documented radiographic evidence of a pancreatic abnormality such as a pancreatic cyst.

* High Risk Group 1 (familial pancreatic cancer relatives):

  * \>/=55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and
  * Come from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and
  * Have a first-degree relationship with at least one of the relatives with pancreatic cancer.
  * If there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened.
* High Risk Group 2 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~10% or higher):

  * \>/=40 years old and the Patient is a carrier of FAMMM (p16/CDKN2A) mutation regardless of family pancreas cancer history.

OR

* \>/= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and the Patient is a carrier of a known BRCA2, ATM, PALB2 mutation.
* Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.

  o High Risk Group 3 (Germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of \~5%):
* \>/= 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and
* The patient is a carrier of a known, BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is \> 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened.
* Persons with known genetic mutation should have proof of mutation status. Those who had research-related genetic testing must have confirmation by a clinical CLIA-certified laboratory.
* Cohort A: Patients must have a pancreatic imaging abnormality that is being followed by pancreatic imaging surveillance (EUS and/or MRI and /or CT), such as a pancreatic cyst consistent with an IPMN or parenchymal abnormalities consistent with PanIN.

  * Cohort B: Patients must have clinical, radiographic, or histologic evidence of pancreatic cystic neoplasm with high-risk features warranting surgical resection per the discretion of the treating hepatobiliary surgeon.
  * Cohort B: Patients must have cystic fluid testing that demonstrates the presence of one of the six KRAS mutations included in the study vaccine.
* Patients must have adequate organ and marrow function defined by study-specified laboratory tests prior to initial study drug.
* Ability to understand and willingness to sign a written informed consent document.
* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.
* Men must use acceptable form of birth control while on study.

Exclusion Criteria:

* If expected to require any other form of systemic or localized antineoplastic therapy while on study.
* Within 4 weeks prior to first dose of study drug.

  o Any systemic or topical corticosteroids at immunosuppressive agents.
* Within 4 weeks prior to first dose of study drug.

  * Any investigational device.
  * Has received a live vaccine.
  * Received any allergen hyposensitization therapy.
  * Any major surgery.
* Infection with HIV or hepatitis B or C.
* Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements monoclonal antibody.
* Has a diagnosis of immunodeficiency.
* Any other sound medical, psychiatric, and/or social reason as determined by the Investigator.
* Unwilling or unable to follow the study schedule for any reason.
* Are pregnant or breastfeeding.

Primary outcomes:
measure: Number of participants experiencing study drug-related toxicities
timeFrame: 1.5 years
measure: Maximal percentage of change of interferon (IFN-γ) producing mutant-KRAS-specific CD8 and CD4 T cells
timeFrame: 17 weeks
Secondary outcomes:
measure: Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 5 weeks.
timeFrame: Baseline, 5 weeks (Cohort A)
measure: Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 13 weeks.
timeFrame: Baseline, 13 weeks (Cohort A)
measure: Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 17 weeks.
timeFrame: Baseline,17 weeks (Cohort A)
Other outcomes:
measure: Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 1 weeks.
timeFrame: Baseline, 1 week (Cohort B)
measure: Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 4 weeks.
timeFrame: Baseline, 4 weeks (Cohort B)
measure: Fold change in interferon-producing mutant-KRAS-specific CD8 and CD4 T cells at 8 weeks.
timeFrame: Baseline, 8 weeks (Cohort B)
Locations:
city: Baltimore
country: United States
facility: Sidney Kimmel Comprehensive Cancer Center
state: Maryland
Study officials:
affiliation: Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Medical Institution
name: Nilofer Azad, MD
role: PRINCIPAL_INVESTIGATOR
References: